Skip to content
10-Q

Quarterly Report

Lazuriton Nano Biotechnology (U.S.A.) Inc.

0001640334-21-002085

← back to feed
Filed
Sep 2, 2021 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2020 · Jun 30, 2020 100M sh
Current Liabilities Q2 2020 · Jun 30, 2020 $291.36K
Current Liabilities Q2 2020 · Dec 31, 2019 $269.88K
Total Liabilities Q2 2020 · Jun 30, 2020 $291.36K
Total Liabilities Q2 2020 · Dec 31, 2019 $269.88K
Current Assets Q2 2020 · Jun 30, 2020 $1.35K
Current Assets Q2 2020 · Dec 31, 2019 $1.35K
Total Assets Q2 2020 · Jun 30, 2020 $1.35K
Total Assets Q2 2020 · Dec 31, 2019 $1.35K
Gross Profit Q2 2020 · Jun 30, 2020 $0
Gross Profit Q2 2020 · Jun 30, 2020 $0
Gross Profit Q2 2020 · Jun 30, 2019 $0
Gross Profit Q2 2020 · Jun 30, 2019 $0
Cost Of Revenue Q2 2020 · Jun 30, 2020 $0
Cost Of Revenue Q2 2020 · Jun 30, 2020 $0
Cost Of Revenue Q2 2020 · Jun 30, 2019 $0
Cost Of Revenue Q2 2020 · Jun 30, 2019 $0
Operating Cash Flow Q2 2020 · Jun 30, 2019 $150
Cash And Equivalents Q2 2020 · Jun 30, 2019 $1.35K
Cash And Equivalents Q2 2020 · Dec 31, 2018 $1.2K
Stockholders Equity Q2 2020 · Jun 30, 2019 −$231.84K
Stockholders Equity Q2 2020 · Mar 31, 2019 −$217.37K
Stockholders Equity Q2 2020 · Dec 31, 2018 −$196.76K
Sga Expense Q2 2020 · Jun 30, 2019 $14.47K
Sga Expense Q2 2020 · Jun 30, 2019 $35.08K
Net Income Q2 2020 · Jun 30, 2019 −$14.47K
Net Income Q2 2020 · Jun 30, 2019 −$35.08K
Net Income Q2 2020 · Mar 31, 2019 −$20.61K
Operating Income Q2 2020 · Jun 30, 2019 −$14.47K
Operating Income Q2 2020 · Jun 30, 2019 −$35.08K
Revenue Q2 2020 · Jun 30, 2019 $0
Revenue Q2 2020 · Jun 30, 2019 $0